Peptide Pipeline Tracker
Peptides and related molecules currently in clinical development. Track progress from preclinical research through Phase 3 trials.
Retatrutide
LY3437943
First-in-class triple incretin agonist showing up to 24% body weight loss in Phase 2 trials. Currently in multiple Phase 3 studies for obesity and type 2 diabetes.
Survodutide
BI 456906
Dual agonist targeting both GLP-1 and glucagon receptors. Phase 3 trials underway for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Orforglipron
LY3502970
Small molecule oral GLP-1 receptor agonist that does not require injection. Phase 3 trials ongoing for obesity and type 2 diabetes with once-daily dosing.
CagriSema
Cagrilintide + Semaglutide
Fixed-ratio combination of cagrilintide (long-acting amylin analog) and semaglutide. Phase 3 trials showed up to 25% weight loss, exceeding semaglutide alone.
Efinopegdutide
MK-6024
Long-acting dual agonist peptide showing potent liver fat reduction. Phase 2b results demonstrated significant MASH resolution and fibrosis improvement. Now in Phase 3 for MASH.
Mazdutide
IBI362 / LY3305677
Oxyntomodulin-based dual agonist approved in China, Phase 3 globally. Showed ~15% body weight loss at 48 weeks with favorable GI tolerability compared to semaglutide.
Petrelintide
ZP8396
Next-generation amylin analog designed for once-weekly dosing. Being studied as monotherapy and in combination with semaglutide for enhanced weight loss beyond GLP-1 alone.
Pemvidutide
ALT-801
Dual agonist peptide being developed for obesity and MASH. Phase 2 data showed significant weight loss and improvements in liver fat reduction.
Ecnoglutide
XW003
Novel long-acting GLP-1 receptor agonist with once-weekly dosing. Phase 2 studies demonstrated competitive weight loss results with favorable tolerability.
MariTide
AMG 133
Unique bispecific molecule combining GIP receptor antagonism with GLP-1 agonism. Monthly or less frequent dosing with sustained weight loss even after treatment cessation in early trials.
Bimagrumab
BYM338
Anti-myostatin antibody that increases lean muscle mass while reducing fat. Being studied in combination with semaglutide to preserve muscle during GLP-1-induced weight loss.
VK2735
VK2735
Subcutaneous and oral formulations in development. Phase 2 showed up to 14.7% weight loss at 13 weeks — one of the fastest onset profiles in the class. Oral version entering trials.
Resmetirom
MGL-3196
First FDA-approved therapy for MASH (as Rezdiffra). Ongoing Phase 2 studies exploring combination with GLP-1 agonists for enhanced liver and metabolic outcomes.
HRS-7535
HRS-7535
Second-generation triple agonist competing with retatrutide. Phase 1 data showed rapid and substantial weight loss. Enrolling Phase 2 studies globally.
Solnatide
AP301
Inhaled peptide that activates epithelial sodium channels in the lung to clear pulmonary edema. Showed significant improvement in ventilation parameters in ARDS patients.
Dasiglucagon
ZP4207
Stable liquid glucagon analog for continuous subcutaneous infusion. Approved for severe hypoglycemia (as Zegalogue), now in trials for congenital hyperinsulinism in children.
NNC0487-0111
Amylin + Cagrilintide analog
Next-generation amylin analog with extended half-life enabling monthly dosing. Being studied as add-on to semaglutide for patients who plateau on GLP-1 monotherapy.
Taldefgrobep Alfa
BHV-2000
Myostatin inhibitor that promotes skeletal muscle growth. Phase 2 in SMA showed increased muscle mass. Potential applications in age-related sarcopenia and cachexia.
AOD-9604 (Injectable)
AOD-9604
C-terminal fragment of human growth hormone (amino acids 177-191) that stimulates lipolysis without the growth-promoting effects of full hGH. Also being studied for cartilage repair in OA.
Danuglipron
PF-06882961
Oral small molecule GLP-1 receptor agonist. Pfizer resumed development with a modified-release formulation after initial twice-daily dosing showed tolerability challenges.
Tozorakimab
MEDI3506
Antibody targeting IL-33 alarmin pathway. Being studied in combination with peptide-based anti-inflammatory agents for chronic respiratory disease.
LY3841024
LY3841024
Oral formulation of a triple incretin agonist. If successful, would be the first oral triple agonist — combining the efficacy of retatrutide with the convenience of a pill.
CT-996
CT-996
Next-generation oral GLP-1 agonist designed for once-daily dosing with improved bioavailability. Early clinical data showed promising weight loss signals.
INV-202
INV-202
Peripherally restricted cannabinoid CB1 inverse agonist targeting liver and adipose tissue. Acquired by Novo Nordisk for metabolic disease pipeline expansion.
GUBamy
Dual amylin/calcitonin agonist
Novel dual agonist targeting both amylin and calcitonin receptors for synergistic appetite suppression and metabolic improvement beyond what either pathway achieves alone.
NVL-655
NVL-655
Intranasal peptide-based CGRP antagonist for acute migraine treatment. Offers faster onset than oral CGRP drugs with targeted CNS delivery via nasal mucosa.
ERX-1000
ERX-1000
First orally bioavailable leptin pathway activator. Designed to overcome leptin resistance — a key driver of weight regain after diet-induced weight loss.
AZD5004
AZD5004
Long-acting dual agonist with potential for monthly dosing. AstraZeneca's entry into the metabolic peptide space following their $2B investment in obesity R&D.
KY-200
KY-200
Oral gut-restricted peptide that activates GLP-1 receptors locally in the intestine without systemic absorption. May eliminate the nausea common with systemic GLP-1 agonists.
BI 1820237
BI 1820237
Peptide-derived antibody targeting the IL-36 receptor. Being developed for rare inflammatory skin conditions with limited treatment options.
MOTS-c Analogs
Next-gen mitochondrial peptides
Synthetic analogs of the mitochondrial open reading frame peptide MOTS-c, which activates AMPK and has shown exercise-mimetic effects. Multiple groups pursuing improved stability and delivery.
Humanin Analogs
HNG / Colivelin derivatives
Stabilized analogs of the cytoprotective peptide humanin. Shown to protect against amyloid-beta toxicity, oxidative stress, and ischemia in animal models. Multiple groups racing to clinical candidates.
FOXO4-DRI
FOXO4-D-Retro-Inverso
D-retro-inverso peptide that selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction. Restored fitness and fur density in aged mice. Cleara is advancing toward IND.
Epithalon (Synthetic Epithalamin)
Ala-Glu-Asp-Gly
Synthetic tetrapeptide based on epithalamin from the pineal gland. Activates telomerase, extending telomere length in human somatic cells. Extensive preclinical data on lifespan extension in animal models.
SS-31 (Elamipretide) Next-Gen
MTP-131 derivatives
Next-generation analogs of elamipretide with improved stability. Targets inner mitochondrial membrane, stabilizing cardiolipin and restoring bioenergetics. Original compound showed promise in Barth syndrome.
Thymalin Analogs
Synthetic thymic peptides
Stabilized derivatives of thymic peptides (thymalin, thymulin) that regenerate T-cell diversity and reverse age-related thymic involution. Shown to restore immune function in aged animal models.
KPV (Alpha-MSH Fragment)
Lys-Pro-Val
C-terminal tripeptide of alpha-MSH with potent anti-inflammatory properties without melanocortin receptor activation. Oral bioavailability makes it a candidate for IBD therapeutics.
Dihexa
N-hexanoic-Tyr-Ile-(6)aminohexanoic amide
Angiotensin IV analog that is 7 orders of magnitude more potent than BDNF at promoting new synapse formation. Shown to reverse cognitive deficits in animal models of dementia. IND-enabling studies underway.
DSIP Analogs
Delta sleep-inducing peptide derivatives
Stabilized analogs of delta sleep-inducing peptide with improved half-life. Promotes slow-wave sleep without the dependency risk of GABAergic drugs. Also shows analgesic and stress-reducing properties.
GHK-Cu Next-Gen (Topical/Injectable)
Gly-His-Lys:Cu(II) derivatives
Enhanced formulations of the copper-binding tripeptide GHK-Cu. Promotes collagen synthesis, attracts immune cells, and activates tissue remodeling genes. Injectable versions being developed for systemic anti-fibrotic applications.
Selank Next-Gen
Tuftsin analog derivatives
Next-generation analogs of selank (heptapeptide tuftsin derivative) with improved BBB penetration and longer half-life. Dual anxiolytic-nootropic profile without sedation or addiction potential.
PT-141 Long-Acting
Bremelanotide depot formulation
Depot/sustained-release formulation of bremelanotide (Vyleesi) to extend dosing from on-demand injection to weekly or monthly administration. Would significantly improve patient compliance.
LL-37 Analogs
Cathelicidin derivatives
Engineered variants of the human cathelicidin LL-37 with enhanced antimicrobial potency and reduced toxicity. Active against MRSA, biofilms, and multidrug-resistant gram-negative bacteria.
Pipeline data sourced from SEC filings, company press releases, and ClinicalTrials.gov. Development stages and timelines are subject to change. This tracker is for informational purposes only and does not constitute medical or investment advice.
Last reviewed: March 2026